Lung Cancer & Vascular Invasion: Predicting Recurrence Risk

Lung cancer remains the most significant cause of cancer-related deaths globally, surpassing the combined toll of breast, prostate and colon cancers in the United States. For those diagnosed with lung adenocarcinoma, the most common form of primary lung cancer, the possibility of recurrence even after successful surgical removal is a persistent concern. Now, research suggests a potential pathway to better predict which tumors will return: identifying specific gene expression patterns associated with vascular invasion before surgery.

Understanding Vascular Invasion and Recurrence

The key lies in a process called vascular invasion, where cancer cells grow into nearby blood vessels. This allows the tumor to spread, increasing the risk of recurrence. Pathologists routinely examine tissue samples after surgery to identify areas of vascular invasion. Even though, this information comes too late to influence the extent of the initial surgery. If surgeons could identify tumors likely to exhibit vascular invasion before operating, they might opt for more aggressive surgical approaches – like lobectomy (removal of an entire lobe of the lung) rather than wedge resection (removal of a smaller, wedge-shaped piece) – to reduce the chance of the cancer returning.

A recent study, published in the journal JTCVS Open, investigated whether a new pathologic classification system could facilitate identify these high-risk tumors. Researchers at multiple institutions retrospectively analyzed data from over 290 patients who underwent either wedge resection or lobectomy for stage I/0 lung adenocarcinomas measuring 2.0 cm or less. The study focused on a classification system that distinguishes between “indolent low malignant potential” (LMP) and “aggressive angioinvasive” adenocarcinomas. The full study details are available here.

Reproducibility and Outcomes with Wedge Resection

The researchers found that the angioinvasive adenocarcinoma classification was reproducible among pathologists, meaning different experts tended to agree on whether a tumor fell into this aggressive category. Critically, they observed that angioinvasive adenocarcinoma (present in 21-27% of cases) was strongly associated with worse outcomes when patients were treated with wedge resection compared to lobectomy. Specifically, 5-year recurrence-free survival was 57% for those with angioinvasive tumors treated with wedge resection, compared to 85% for those treated with lobectomy (P = .007). Five-year disease-free survival was also lower in the wedge resection group with angioinvasive tumors (70% vs 90%, P = .043). While the difference in 7-year overall survival wasn’t statistically significant (37% vs 58%, P = .143), the trend pointed towards a similar disadvantage for the wedge resection group.

Beyond the Study: Broader Context of Lung Cancer Treatment

These findings build upon a growing body of research highlighting the importance of vascular invasion in lung cancer prognosis. Lung Cancer Journal research emphasizes that approximately 15% of patients undergoing surgery for stage I lung adenocarcinoma experience recurrence, and identifying those at highest risk is crucial for optimizing treatment strategies. Recent randomized controlled trials, such as JCOG0802 and CALGB140503, have demonstrated that sublobar resection (like wedge resection) can be a viable option for smaller tumors (≤2.0 cm). However, this study suggests that sublobar resection may not be appropriate for all patients, particularly those with angioinvasive features.

The Promise of Pre-Surgical Biomarkers

Currently, identifying vascular invasion relies on post-operative pathological examination. The real breakthrough would be to predict which tumors are likely to exhibit this aggressive behavior before surgery. Research published in Nature explores the potential of identifying gene expression patterns associated with vascular invasion pre-operatively. This could involve analyzing biopsy samples using advanced molecular techniques to detect biomarkers indicative of an increased risk of vascular invasion. The goal is to move towards a more personalized approach to lung cancer surgery, tailoring the extent of resection to the individual patient’s risk profile.

Limitations and Considerations

It’s important to note the limitations of the JTCVS Open study. It was a retrospective analysis, meaning the researchers looked back at data already collected. Retrospective studies can be prone to biases and may not fully reflect real-world clinical practice. The study also involved a relatively compact sample size, and the findings may not be generalizable to all populations of patients with lung adenocarcinoma. The study focused specifically on tumors ≤2.0 cm; the results may not apply to larger tumors.

What Comes Next: Refining Risk Stratification

The development of reliable pre-surgical biomarkers for vascular invasion is an ongoing area of research. Future studies will need to validate these findings in larger, prospective cohorts. Researchers are also exploring the potential of combining multiple biomarkers to create a more comprehensive risk prediction model. This could involve integrating gene expression data with other clinical and imaging features to provide a more accurate assessment of a patient’s risk of recurrence. The ultimate aim is to refine risk stratification and ensure that patients receive the most appropriate surgical treatment based on their individual tumor characteristics. Ongoing clinical trials are evaluating the impact of different surgical approaches and adjuvant therapies in patients with varying risk profiles, which will further inform treatment guidelines.